Franklin Biotechnology Discovery Fund

Fund Description

The fund seeks capital appreciation by investing at least 80% of its net assets in securities of biotechnology companies and discovery research firms including those involved in fields such as genomics, genetic engineering, and gene therapy, as well as health care, pharmaceuticals and agriculture.

Strategy Statement

"With the increasing demand for new medical treatments driving earnings growth, and many profitable firms to choose from, we believe now is an exciting time to invest in the biotechnology sector."

Evan McCulloch, CFA®

Management

Evan McCulloch, CFA

Evan McCulloch, CFA®

  • Joined Franklin Templeton in 1992
  • Managed Fund Since 1997
Wendy Lam, Ph.D

Wendy Lam, Ph.D

  • Joined Franklin Templeton in 2016
  • Managed Fund Since 2018
Steve Kornfeld, CFA

Steve Kornfeld, CFA®

  • Joined Franklin Templeton in 2001
  • Managed Fund Since 2015

Rating

Overall Morningstar Rating As of 10/31/2018

Rating Category: Health

Morningstar
The fund's overall Morningstar Rating measures risk-adjusted returns and is derived from a weighted average of the performance figures associated with its 3-, 5- and 10-year (if applicable) rating metrics.

Historical Morningstar Rating As of 10/31/2018

Years Ratings Funds
in category
3
1 Stars
130
5
1 Stars
121
10
2 Stars
98

Morningstar Style Box As of09/30/2018

Strategy, Benefits, Results

Strategy

  • We take a bottom-up approach to individual stock selection.
  • We look for companies that possess products with favorable competitive profiles, large market opportunities and strong intellectual property.
  • We favor companies with excellent management, strong financial characteristics and attractive valuations.
  • Our San Francisco Bay Area location is shared by many leading biotechnology companies, enabling us to easily attend scientific meetings and symposia, and to consult with community and academic physicians.

Benefits

  • Participate in trends moving markets. Invest in innovative sectors—technology, medicine, global communications—we believe are poised for long-term growth.
  • Diversification. By adding investments from different sectors to your portfolio, you may take advantage of expanding and contracting economic cycles.
  • Experienced management. Same lead portfolio manager since the fund's inception in 1997.

Investing In The Fund

What Are the Risks?

  • All investments involve risks, including possible loss of principal.
  • The fund is a non-diversified fund that concentrates in a single sector, which involves risks such as patent considerations, product liability, government regulatory requirements, and regulatory approval for new drugs and medical products.
  • Biotechnology companies often are small and/or relatively new.
  • Smaller companies can be particularly sensitive to changes in economic conditions and have less certain growth prospects than larger, more established companies and can be volatile, especially over the short term.
  • The fund may also invest in foreign companies, which involve special risks, including currency fluctuations and political uncertainty.
  • These and other risks are described more fully in the fund’s prospectus.

Minimum Investment

See Prospectus

How Financial Advisors Help You

Speak to your advisor about whether this fund is appropriate for you.

Learn more from FINRA about How to Find and Work with an Investment Professional.

You need Adobe Acrobat Reader 6.0 or higher to view and print PDF documents. Download a free version from Adobe's website.